Published in Medicine (Baltimore) on May 01, 1991
Camurati-Engelmann disease: unique variant featuring a novel mutation in TGFβ1 encoding transforming growth factor beta 1 and a missense change in TNFSF11 encoding RANK ligand. J Bone Miner Res (2011) 1.71
Primary hypertrophic osteoarthropathy with myelofibrosis. Rheumatol Int (2007) 1.42
Pachydermoperiostosis-critical analysis with report of five unusual cases. Eur J Pediatr (2007) 1.01
Pachydermoperiostosis accompanied by heart failure. J Cardiovasc Ultrasound (2009) 0.90
Involvement of Wnt signaling in dermal fibroblasts. Am J Pathol (2009) 0.86
Bilateral ptosis due to a rare cause-pachydermoperiostosis. J Clin Diagn Res (2013) 0.82
Primary hypertrophic osteoarthropathy. Rheumatol Int (2010) 0.81
Two cases with pachydermoperiostosis and discussion of tamoxifen citrate treatment for arthralgia. Clin Rheumatol (2007) 0.79
Enlarged hands and feet - Not always acromegaly. Indian J Endocrinol Metab (2012) 0.75
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 6.36
EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.59
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Development of oesophageal involvement in a subject with pemphigus vulgaris: a case report and review of the literature. J Eur Acad Dermatol Venereol (2002) 1.79
Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum (1995) 1.67
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
Effects of capsaicin on the metabolism of rheumatoid arthritis synoviocytes in vitro. Ann Rheum Dis (1990) 1.47
Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2003) 1.45
Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol (1997) 1.43
High prevalence of circulating autoantibodies against thyroid hormones in vitiligo and correlation with clinical and historical parameters of patients. Br J Dermatol (2014) 1.42
Appearance of duodenal folds and untreated adult celiac disease. Gastrointest Endosc (1993) 1.39
Suppression of autoantibodies to factor VIII and correction of factor VIII deficiency with a combined steroid-cyclophosphamide-porcine factor VIII treatment in a patient with rheumatoid arthritis. J Intern Med (1992) 1.38
Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF-α-treatment. J Eur Acad Dermatol Venereol (2011) 1.38
Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol (1993) 1.30
European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol (2006) 1.30
Hip geometry, bone mineral distribution, and bone strength in European men and women: the EPOS study. Bone (2000) 1.23
Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study. Osteoporos Int (2001) 1.20
Multidimensional non-linear laser imaging of Basal Cell Carcinoma. Opt Express (2007) 1.15
Hyaluronic acid in cutaneous intrinsic aging. Int J Dermatol (1994) 1.15
The use of silicone gel in the treatment of fresh surgical scars: a randomized study. Clin Exp Dermatol (2009) 1.12
Pachydermoperiostosis (primary hypertrophic osteoarthropathy): report of a case with evidence of endothelial and connective tissue involvement. Ann Rheum Dis (1989) 1.12
Primary hypertrophic osteoarthropathy: clinical, radiologic, and scintigraphic characteristics. Arch Med Res (2001) 1.11
Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum (2003) 1.10
The spectrum of dermatological symptoms of pachydermoperiostosis (primary hypertrophic osteoarthropathy): a genetic, cytogenetic and ultrastructural study. Clin Exp Rheumatol (1992) 1.08
Pulmonary arterial hypertension in systemic sclerosis: diagnostic pathway and therapeutic approach. Ann Rheum Dis (2005) 1.03
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant (2004) 1.01
Cutaneous fibrinolytic activity in primary hypertrophic osteoarthropathy. Scand J Rheumatol (1987) 0.97
Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmun Rev (2012) 0.96
Combined non-linear laser imaging (two-photon excitation fluorescence microscopy, fluorescence lifetime imaging microscopy, multispectral multiphoton microscopy) in cutaneous tumours: first experiences. J Eur Acad Dermatol Venereol (2009) 0.95
Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology (2000) 0.94
Alopecia areata: immunohistochemistry and ultrastructure of infiltrate and identification of adhesion molecule receptors. Int J Dermatol (1996) 0.94
Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis (2004) 0.94
Whom to treat? The contribution of vertebral X-rays to risk-based algorithms for fracture prediction. Results from the European Prospective Osteoporosis Study. Osteoporos Int (2006) 0.93
Neurogenic influences in arthritis: potential modification by capsaicin. J Rheumatol (1995) 0.92
Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum (1998) 0.92
Immunological abnormalities in a group of patients with limited cutaneous systemic sclerosis and prominent vascular disease. Autoimmunity (1990) 0.91
Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol (1998) 0.91
Nonlinear laser imaging of skin lesions. J Biophotonics (2008) 0.91
Itch in psoriasis: epidemiology, clinical aspects and treatment options. Clin Cosmet Investig Dermatol (2009) 0.90
Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann Rheum Dis (2002) 0.90
Vascular based non conventional dye laser treatment for basal cell carcinoma. Dermatol Ther (2008) 0.90
Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment. Rheumatology (Oxford) (2006) 0.90
Localized scleroderma. Clin Dermatol (1994) 0.89
Intense pulsed light in the treatment of non-aesthetic facial and neck vascular lesions: report of 85 cases. J Eur Acad Dermatol Venereol (2011) 0.89
Common variable immunodeficiency in vitiligo. G Ital Dermatol Venereol (2010) 0.88
Isomorphic versus isotopic response: data and hypotheses. J Eur Acad Dermatol Venereol (2003) 0.88
Falls explain between-center differences in the incidence of limb fracture across Europe. Bone (2002) 0.88
Role of specific membrane receptors in urokinase-dependent migration of human keratinocytes. J Invest Dermatol (1990) 0.87
Cellular neurothekeoma in a girl: could oestrogens favour the development and growth of this rare tumour? J Eur Acad Dermatol Venereol (2008) 0.87
Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface. Life Sci (1998) 0.87
Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol (2011) 0.87
Fractional CO2 laser: a novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repair. Dermatol Ther (2009) 0.87
Fragile X founder chromosomes in Italy: a few initial events and possible explanation for their heterogeneity. Am J Med Genet (1996) 0.86
Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment: a collaboration between dermatologists and infectivologists. J Eur Acad Dermatol Venereol (2012) 0.86
Photodynamic treatment for viral infections of the skin. G Ital Dermatol Venereol (2009) 0.86
Microstructural disorders of tunica albuginea in patients affected by Peyronie's disease with or without erection dysfunction. J Urol (1993) 0.86
Photodynamic therapy: off-label and alternative use in dermatological practice. Photodiagnosis Photodyn Ther (2008) 0.86
Oxidative stress in Systemic Sclerosis. Mol Cell Biochem (1999) 0.86
[A case of Pellizzari-Jadasshon anetoderma. Clinical and immunopathologic study]. G Ital Dermatol Venereol (1986) 0.85
Circulating levels of Nepsilon-(carboxymethyl)lysine are increased in systemic sclerosis. Rheumatology (Oxford) (2006) 0.85
Colchicine treatment in a case of pachydermoperiostosis with acroosteolysis. Rheumatol Int (1988) 0.84
Systemic sclerosis. A clinical overview. Adv Exp Med Biol (1999) 0.84
Allergic contact dermatitis from henna temporary tattoo. J Eur Acad Dermatol Venereol (2006) 0.84
Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). Ann Rheum Dis (2001) 0.84
Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis. Rheumatology (Oxford) (2007) 0.84
A severe complication of anti-TNF alfa treatment. G Ital Dermatol Venereol (2010) 0.83
Substance P provokes cutaneous erythema and edema through a histamine-independent pathway. Int J Dermatol (1992) 0.83
Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes. Rheumatology (Oxford) (2005) 0.83
Raynaud's phenomenon (primary or secondary to systemic sclerosis). The usefulness of laser-Doppler flowmetry in the diagnosis. Int Angiol (2001) 0.83
Familial scleroderma: do environmental factors, genes and microchimerism share the same relevance? J Eur Acad Dermatol Venereol (2001) 0.83
Microstructural disorders of tunica albuginea in patients affected by impotence. Eur Urol (1994) 0.83
Increased cutaneous fibrinolytic activity in aquagenic pruritus. Int J Dermatol (1986) 0.82
Psychoactive drugs and skin. J Eur Acad Dermatol Venereol (2003) 0.82
Psoriatic disease: concepts and implications. J Eur Acad Dermatol Venereol (2010) 0.82
High levels of substance P in rheumatoid arthritis synovial fluid. Lack of substance P production by synoviocytes in vitro. Clin Exp Rheumatol (1991) 0.82
Increased circulating nerve growth factor is directly correlated with disease activity in juvenile chronic arthritis. Ann Rheum Dis (1996) 0.82
Erythema elevatum diutinum. Int J Dermatol (1994) 0.81
Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. J Clin Endocrinol Metab (1997) 0.81
Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. Curr Med Res Opin (2009) 0.81
Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients. J Eur Acad Dermatol Venereol (2010) 0.81
Neonatal monitoring to assess risk for hypertension. Postgrad Med (1986) 0.81
Cell infiltrate in progressive pigmented purpura (Schamberg's disease): immunophenotype, adhesion receptors, and intercellular relationships. Int J Dermatol (1995) 0.81
Cigarette smoking, wound healing, and face-lift. Clin Dermatol (1998) 0.81
Nerve growth factor circulating levels are increased in Kawasaki disease: correlation with disease activity and reduced angiotensin converting enzyme levels. J Rheumatol (1996) 0.81
Effect of melatonin on normal and sclerodermic skin fibroblast proliferation. Clin Exp Rheumatol (1997) 0.81
Pathogenesis of pemphigus. The role of epidermal plasminogen activators in acantholysis. Int J Dermatol (1985) 0.81
Somatostatin treatment of psoriatic arthritis. Int J Dermatol (1988) 0.81